Nevro Corp. (NVRO)
USD 5.84
(0.0%)
USD 5.84
(0.0%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 117.61 Million USD | 53.16% |
| 2022 | 76.79 Million USD | -41.83% |
| 2021 | 132 Million USD | -53.3% |
| 2020 | 282.63 Million USD | 144.98% |
| 2019 | 115.37 Million USD | 14.09% |
| 2018 | 101.12 Million USD | -1.02% |
| 2017 | 102.17 Million USD | 5.62% |
| 2016 | 96.73 Million USD | 243.74% |
| 2015 | -67.29 Million USD | -1065.1% |
| 2014 | -5.77 Million USD | 53.45% |
| 2013 | -12.4 Million USD | -120.88% |
| 2012 | -5.61 Million USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | 133.45 Million USD | 13.47% |
| 2024 Q2 | 167.95 Million USD | 25.85% |
| 2023 Q1 | 131.89 Million USD | 71.76% |
| 2023 FY | 117.61 Million USD | 53.16% |
| 2023 Q3 | 128.75 Million USD | -0.85% |
| 2023 Q2 | 129.85 Million USD | -1.55% |
| 2023 Q4 | 117.61 Million USD | -8.65% |
| 2022 Q1 | 150.66 Million USD | 14.14% |
| 2022 Q2 | 90.17 Million USD | -40.15% |
| 2022 Q3 | 67.34 Million USD | -25.32% |
| 2022 Q4 | 76.79 Million USD | 14.03% |
| 2022 FY | 76.79 Million USD | -41.83% |
| 2021 Q2 | 17.83 Million USD | -92.7% |
| 2021 Q3 | 84.19 Million USD | 372.23% |
| 2021 Q4 | 132 Million USD | 56.77% |
| 2021 Q1 | 244.19 Million USD | -13.6% |
| 2021 FY | 132 Million USD | -53.3% |
| 2020 FY | 282.63 Million USD | 144.98% |
| 2020 Q3 | 205.15 Million USD | 367.01% |
| 2020 Q1 | 45.62 Million USD | -60.45% |
| 2020 Q4 | 282.63 Million USD | 37.77% |
| 2020 Q2 | 43.92 Million USD | -3.72% |
| 2019 FY | 115.37 Million USD | 14.09% |
| 2019 Q2 | 115.65 Million USD | -15.35% |
| 2019 Q3 | 130.26 Million USD | 12.63% |
| 2019 Q1 | 136.62 Million USD | 35.1% |
| 2019 Q4 | 115.37 Million USD | -11.43% |
| 2018 Q1 | 119.17 Million USD | 16.64% |
| 2018 Q3 | 129.13 Million USD | 19.78% |
| 2018 Q4 | 101.12 Million USD | -21.69% |
| 2018 FY | 101.12 Million USD | -1.02% |
| 2018 Q2 | 107.8 Million USD | -9.54% |
| 2017 Q2 | 116.65 Million USD | -3.29% |
| 2017 FY | 102.17 Million USD | 5.62% |
| 2017 Q4 | 102.17 Million USD | 2.98% |
| 2017 Q3 | 99.21 Million USD | -14.94% |
| 2017 Q1 | 120.62 Million USD | 24.7% |
| 2016 Q4 | 96.73 Million USD | 3.17% |
| 2016 Q1 | -28.95 Million USD | 56.97% |
| 2016 FY | 96.73 Million USD | 243.74% |
| 2016 Q2 | 84.09 Million USD | 390.4% |
| 2016 Q3 | 93.76 Million USD | 11.5% |
| 2015 Q1 | -2.41 Million USD | 58.19% |
| 2015 FY | -67.29 Million USD | -1065.1% |
| 2015 Q2 | -39.08 Million USD | -1518.34% |
| 2015 Q4 | -67.29 Million USD | 0.84% |
| 2015 Q3 | -67.86 Million USD | -73.65% |
| 2014 Q2 | -17.39 Million USD | -12.87% |
| 2014 Q1 | -15.41 Million USD | -24.19% |
| 2014 Q3 | -14.47 Million USD | 16.78% |
| 2014 Q4 | -5.77 Million USD | 60.1% |
| 2014 FY | -5.77 Million USD | 53.45% |
| 2013 FY | -12.4 Million USD | -120.88% |
| 2013 Q4 | -12.4 Million USD | 0.0% |
| 2013 Q1 | 30.61 Million USD | 0.0% |
| 2012 FY | -5.61 Million USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Abbott Laboratories | 8.97 Billion USD | 98.69% |
| Allurion Technologies Inc. | 3.82 Million USD | -2978.796% |
| Artivion, Inc. | 300.4 Million USD | 60.849% |
| Avanos Medical, Inc. | 121.4 Million USD | 3.122% |
| Butterfly Network, Inc. | -109.6 Million USD | 207.3% |
| Butterfly Network, Inc. | -109.6 Million USD | 207.3% |
| Bio-Rad Laboratories, Inc. | 1 Billion USD | 88.262% |
| Boston Scientific Corporation | 8.62 Billion USD | 98.637% |
| CONMED Corporation | 966.95 Million USD | 87.837% |
| Edwards Lifesciences Corporation | -449.1 Million USD | 126.188% |
| Paragon 28, Inc. | 36.39 Million USD | -223.184% |
| Glaukos Corporation | 290.27 Million USD | 59.483% |
| Globus Medical, Inc. | 53.11 Million USD | -121.438% |
| Inspire Medical Systems, Inc. | -160.69 Million USD | 173.19% |
| Integer Holdings Corporation | 1.01 Billion USD | 88.439% |
| Medtronic plc | 24.76 Billion USD | 99.525% |
| Myomo, Inc. | -6.27 Million USD | 1975.757% |
| Owlet, Inc. | -1.34 Million USD | 8870.327% |
| Penumbra, Inc. | 66.85 Million USD | -75.913% |
| Vicarious Surgical Inc. | -37.99 Million USD | 409.581% |
| Smith & Nephew plc | 2.78 Billion USD | 95.772% |
| Sonendo, Inc. | 26.34 Million USD | -346.473% |
| STERIS plc | 3.17 Billion USD | 96.297% |
| Stryker Corporation | 10.02 Billion USD | 98.827% |
| Vapotherm, Inc. | 102.66 Million USD | -14.555% |
| Zimmer Biomet Holdings, Inc. | 5.57 Billion USD | 97.892% |